iBio (IBIO) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of iBio (NASDAQ: IBIO) in the last few weeks:

• 6/8/2026 – iBio is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $5.00 price target on the stock.
• 6/8/2026 – iBio is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $5.00 price target on the stock.
• 6/7/2026 – iBio was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/5/2026 – iBio is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $6.00 price target on the stock.
• 5/30/2026 – iBio was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/16/2026 – iBio was downgraded by Wall Street Zen from “hold” to “sell”.

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.